Institutional members access full text with Ovid®

Share this article on:

Tregs: application for solid-organ transplantation

Schlieer, Ulrike; Streitz, Mathiasa; Sawitzki, Birgita,b

Current Opinion in Organ Transplantation: February 2012 - Volume 17 - Issue 1 - p 34–41
doi: 10.1097/MOT.0b013e32834ee69f

Purpose of review Transfer of human regulatory T cells (Tregs) has become an attractive therapeutic alternative to improve the long-term outcome in transplantation and thus reduce the side-effects of conventional immunosuppressive drugs. Here, we summarize the recent findings on human Treg subsets, their phenotype and in-vivo function.

Recent findings In the last 2 years, it has become apparent that several Treg subsets exist that specifically regulate Th1-driven, Th2-driven, or Th17-driven immune responses; these subsets are very unstable and rapidly change their phenotype, for example, there is loss of Foxp3 expression upon extensive ex-vivo expansion and only the administration of rapamycin has been shown to be able to interfere reproducibly. New humanized mouse models incorporating human solid-organ grafts have been developed, which have been used to test the human Treg in-vivo function, and the first human Treg-cell products have been tested for safety and efficacy in stem cell transplantation.

Summary With the recent findings, we have gained a better understanding of Treg heterogeneity, plasticity and function. Using the outcomes of clinical trials in stem cell transplantation, we have learned that adoptive therapy of Tregs is well tolerated and we are now awaiting the first result in solid-organ transplantation from the ‘ONE Study’.

aInstitute of Medical Immunology

bBerlin-Brandenburg Center for Regenerative Therapies (BCRT), CVK, Charité University Berlin, Berlin, Germany

Correspondence to Birgit Sawitzki, Institute of Medical Immunology, Charité University Medicine, Augustenburger Platz 1, 13353 Berlin, Germany. Tel: +49 30 450 524 136; fax: +49 30 450 524 907; e-mail:

© 2012 Lippincott Williams & Wilkins, Inc.